Failed pivotal study? You can still have breakthrough therapy status — FDA signals to Resverlogix

A small Canadian biotechnology company has convinced the FDA to reward its sole experimental drug breakthrough therapy status as a preventative therapy for major adverse cardiac events, despite a failed late-stage study.